What restricts the clinical use of nicotinic acid?

Current Vascular Pharmacology

Volumn 9, Issue 4, 2011, Pages 521-530

  Kei, Anastazia ^a   Liberopoulos, Evangelos N ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adverse events, niacin, nicotinic acid, side effects, toxicity, laropiprant

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALLOPURINOL; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILE ACID SEQUESTRANT; FIBRINOGEN; FLUINDOSTATIN; G PROTEIN RECEPTOR 109A; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; LAROPIPRANT; MEMBRANE PROTEIN; MEVINOLIN; NAPROXEN; NICOTINIC ACID; ORGANIC ANION TRANSPORTER 10; PHOSPHATE; PHOSPHOPYRUVATE CARBOXYLASE; PRAVASTATIN; PROSTAGLANDIN D2; PROTHROMBIN; PROTON PUMP INHIBITOR; RECEPTOR; SIMVASTATIN; UNCLASSIFIED DRUG; URIC ACID; WARFARIN;

ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; ADIPOSE TISSUE; AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL PRESSURE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BLOOD PRESSURE; BLURRED VISION; CHOLELITHIASIS; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSLIPIDEMIA; EPIGASTRIC PAIN; ESOPHAGITIS; EXOPHTHALMOS; EYE SWELLING; EYELID DISEASE; FATTY ACID BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; FLUSHING; FULMINANT HEPATIC FAILURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GOUT; HEART RATE; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERURICEMIA; HYPOLIPEMIA; HYPOPHOSPHATEMIA; INSULIN RESISTANCE; KERATITIS; LANGERHANS CELL; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; MACULOPAPULAR RASH; MENTAL DISEASE; MONOTHERAPY; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; ORTHOSTATIC HYPOTENSION; PEPTIC ULCER; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PROTHROMBIN TIME; PRURITUS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TACHYPHYLAXIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; URIC ACID BLOOD LEVEL; URTICARIA; VASCULAR RESISTANCE; VOMITING;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; LIPOPROTEIN(A); NIACIN;

EID: 79960013306     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111796197215     Document Type: Review

References (124)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-9.
2. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009; 5: 901-8.
3. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998; 82: 74U-81U.
4. Vogt A, Kassner U, Hostalek U, et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin 2006; 22: 417-25.
5. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
6. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-30.
7. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and non-vascular mortality. JAMA 2009; 302: 412-23.
8. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
9. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55.
10. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202: 68-75.
11. Tavintharan S, Sivakumar M, Lim SC, et al. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clin Chim Acta 2007; 376: 41-4.
12. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med 2003; 114: 347-53.
13. Cho KH, Kim HJ, Kamanna VS, et al. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta 2010; 1800: 6-15.
14. Sorrentino SA, Besler C, Rohrer L, et al. Endothelialvasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010; 121: 110-22.
15. Shehadah A, Chen J, Zacharek A, et al. Niaspan treatment induces neuroprotection after stroke. Neurobiol Dis 2010 [Epub ahead of print].
16. Salama RH, Nassar AY, Nafady, AA, et al. A novel therapeutic drug (copper nicotinic acid complex) for non-alcoholic fatty liver. Liver Int 2007; 27: 454-64.
17. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009; 20: 467-76.
18. Warady B, Kriley M, Alon U, et al. Nicotinic acid-induced flush. Perit Dial Int 1989; 9: 81-2.
19. Wilkin JK. Why is flushing limited to a mostly facial cutaneous distribution? J Am Acad Dermatol 1988; 19: 309-13.
20. Abbott Laboratories. Niaspan tablets: niacin extended-release tablets.
21. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005; 115: 3634-40.
22. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303: 364-9.
23. Lorenzen A, Stannek C, Lang H, et al. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001; 59: 349-57.
24. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006; 126: 2637-46.
25. Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962; 172: 641-5.
26. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009; 63: 1369-77.
27. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006; 103: 6682-7.
28. Ishida H, Masuhiro Y, Fukushima A, et al. Identification and characterization of novel isoforms of human DP-1: DP-1{alpha} regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner. J Biol Chem 2005; 280: 24642-8.
29. Stern RH, Spence JD, Freeman DJ, et al. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 1991; 50: 66-70.
30. Paolini JF, Mitchel YB, Reyes R, et al. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Int J Clin Pract 2008; 62: 896-904.
31. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94-114.
32. Svedmyr N, Harthon L, Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther 1969; 10: 559-70.
33. Pieper JA. Understanding niacin formulations. Am J Manag Care 2002; 8: S308-14.
34. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000; 86: 35L-40L.
35. McKenney J. Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 2003; 60: 995-1005.
36. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 642-50.
37. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99: 22C-31C.
38. McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained-vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271: 672-7.
39. Christensen NA, Achor RW, Berge KG, et al. Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustainedaction preparations and report of two cases of jaundice. JAMA 1961; 177: 546-50.
40. Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/ laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008; 26: 547-60.
41. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008; 101: 1428-36.
42. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008; 8: 69-81.
43. Cefali EA, Simmons PD, Stanek EJ, et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007; 45: 78-88.
44. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997; 12: 591-6.
45. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006; 60: 707-15.
46. Whelan AM, Price SO, Fowler SF, et al. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992; 34: 165-8.
47. Thakkar RB, Kashyap ML, Lewin AJ, et al. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs 2009; 9: 69-79.
48. Eklund B, Kaijser L, Nowak J, et al. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 1979; 17: 821-30.
49. Kaijser L, Eklund B, Olsson AG, et al. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979; 57: 114-7.
50. Dunn RT, Ford MA, Rindone JP, et al. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995; 2: 478-80.
51. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000; 86: 51L-6L.
52. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol 2008; 101: 14B-9B.
53. TREDAPTIVE product overview. [Online] 2010 Sep 15, [cited 2008]. Available from: http://www.ema.europa.eu/humandocs/ Humans/EPAR/tredaptive/tredaptive.htm.
54. Van Hecken A, Depre M, De Lepeleire I, et al. The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol 2007; 63: 135-41.
55. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62: 1959-70.
56. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant vs. gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 74-81.
57. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009; 49: 416-22.
58. Kei A, Liberopoulos E, Rizos C, et al. The effect of nicotinic acid administration on lipid profile in patients with mixed dyslipidemia]. Hellenic J Atheroscler 2010; 1 (Suppl 1): in press. (Abstract in Greek)
59. FDA Rejects Merck's Cordaptive. [Online] 2010 Sep 15, [cited 2008]. Available from: http://www.businessweek.com/ bwdaily/dnflash/content/apr2008/db20080429_182260.htm
60. Lai E, Wenning LA, Crumley TM et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008; 83: 840-7.
61. Stals H, Vercammen C, Peeters C, et al. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology 1994; 189: 203-6.
62. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004; 5: 1385-98.
63. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008; 83: 470-8.
64. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-4.
65. Boden G, Lebed B, Schatz M, et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50: 1612-7.
66. Poynten AM, Gan SK, Kriketos AD, et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 2003; 52 699-704.
67. Vega GL, Cater NB, Meguro S, et al. Influence of extended-release nicotinic acid on non-esterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005; 95: 1309-13.
68. Choi S, Yoon H, Oh KS, et al. Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment. Metabolism 2010 [Epub ahead of print].
69. Libby A, Meier J, Lopez J, et al. The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin. Metab Syndr Relat Disord 2010; 8: 79-84.
70. Thorpe LE, Upadhyay UD, Chamany S, et al. Prevalence and control of diabetes and impaired fasting glucose in New York City. Diabetes Care 2009; 32: 57-62.
71. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263-70.
72. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568-76.
73. Stamler J. The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977; 82: 52-75.
74. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95: 254-7.
75. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with vs. without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006; 97: 477-9.
76. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
77. Athyros VG, Tziomalos K, Karagiannis A, et al. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother 2010; 11: 1965-70.
78. Association AD. Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 Suppl 1: S11-61.
79. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998; 82: 737-43.
80. Andersson S, Carlson LA, Oro L, et al. Effect of nicotinic acid on gastric secretion of acid in human subjects and in dogs. Scand J Gastroenterol 1971; 6: 693-8.
81. Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology 1988; 95: 930-6.
82. Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol 2004; 138: 639-47.
83. Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 2006; 41: 197-200.
84. Spirn MJ, Warren FA, Guyer DR, et al. Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol 2003; 135: 913-4.
85. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995; 79: 54-6.
86. Jampol LM. Niacin maculopathy. Ophthalmology 1988; 95: 1704-5.
87. Gadegbeku CA, Dhandayuthapani A, Shrayyef MZ, et al. Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. Am J Hypertens 2003; 16: 67-71.
88. Kelly JJ, Lawson JA, Campbell LV, et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 2000; 14: 567-72.
89. Bays HE, Maccubbin D, Meehan AG, et al. Blood pressurelowering effects of extended-release niacin alone and extendedrelease niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther 2009; 31: 115-22.
90. Bays HE, Rader DJ. Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract 2009; 63: 151-9.
91. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98: 1352-64.
92. Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 370-8.
93. Lind L. Vasodilation in resistance arteries is related to the apolipoprotein B/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis 2007; 190: 378-84.
94. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991; 40(Suppl 1): S49-51.
95. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989; 86: 481-3.
96. Gharavi AG, Diamond JA, Smith DA, et al. Niacin-induced myopathy. Am J Cardiol 1994; 74: 841-2.
97. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year followup. JAMA 1990; 264: 3013-7.
98. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000; 85: 1100-5.
99. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J.
100. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52: 1639-45.
101. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of oncedaily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Vs. Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91: 667-72.
102. Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004; 94: 306-11.
103. Gibbons LW, Gonzalez V, Gordon N, et al. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995; 99: 378-85.
104. Gentile S, Tiribelli C, Persico M, et al. Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert's syndrome. J Lab Clin Med 1986; 107: 166-71.
105. Ohkubo H, Musha H, Okuda K. Studies on nicotinic acid interaction with bilirubin metabolism. Dig Dis Sci 1979; 24: 700-4.
106. Gaut ZN, Pocelinko R, Solomon HM, et al. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism 1971; 20: 1031-5.
107. Gershon SL, Fox IH. Pharmacologic effects of nicotinic acid on human purine metabolism. J Lab Clin Med 1974; 84: 179-86.
108. Bahn A, Hagos Y, Reuter S, et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008; 283: 16332-41.
109. Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-51.
110. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10.
111. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
112. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
113. Youssef F, Gupta P, Seifalian AM, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
114. Dearing BD, Lavie CJ, Lohmann TP, et al. Niacin-induced clotting factor synthesis deficiency with coagulopathy. Arch Intern Med 1992; 152: 861-3.
115. Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000; 140: 631-6.
116. Paraskevas KI, Baker DM, Vrentzos GE, et al. The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thromb Res 2008; 122: 1-12.
117. Kakafika AI, Liberopoulos EN, Mikhailidis DP. Fibrinogen: a predictor of vascular disease. Curr Pharm Des 2007; 13: 1647-59.
118. Maccubbin D, Tipping D, Kuznetsova O, et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010; 5: 582-9.
119. Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodiumdependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20: 1378-84.
120. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: a review. QJM 2010; 103: 449-59.
121. Daul AM, Beuhler MC. Niacin toxicity resulting from urine drug test evasion scheme. J Emerg Med 2010 [Epub ahead of printing].
122. Mittal MK, Florin T, Perrone J, et al. Toxicity from the use of niacin to beat urine drug screening. Ann Emerg Med 2007; 50: 587-90.
123. Fischer DJ, Knight LL, Vestal RE. Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital. West J Med 1991; 155: 410-2.
124. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989; 111: 253-5.